{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:15:01Z","timestamp":1780514101748,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13318-023-00856-2","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T07:02:07Z","timestamp":1696662127000},"page":"691-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug\u2013Drug Interaction in Healthy Participants"],"prefix":"10.1007","volume":"48","clinical-trial-number":[{"clinical-trial-number":"nct04829773","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rose","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ogier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Hanh","family":"Le Quan Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"issue":"5","key":"856_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000365770","volume":"5","author":"I H\u00fcning","year":"2014","unstructured":"H\u00fcning I, Gillessen-Kaesbach G. Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation. Mol Syndromol. 2014;5(5):201\u201311. https:\/\/doi.org\/10.1159\/000365770.","journal-title":"Mol Syndromol."},{"issue":"9","key":"856_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrrheum.2010.122","volume":"6","author":"EM Shore","year":"2010","unstructured":"Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol. 2010;6(9):518\u201327. https:\/\/doi.org\/10.1038\/nrrheum.2010.122.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"856_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2106\/00004623-199302000-00009","volume":"75","author":"FS Kaplan","year":"1993","unstructured":"Kaplan FS, Tabas JA, Gannon FH, et al. The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J Bone Jt Surg Am. 1993;75(2):220\u201330. https:\/\/doi.org\/10.2106\/00004623-199302000-00009.","journal-title":"J Bone Jt Surg Am."},{"issue":"3","key":"856_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthr\u00f6m M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650\u20136. https:\/\/doi.org\/10.1002\/jbmr.2728.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"856_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1302\/0301-620x.64b1.7068725","volume":"64","author":"JM Connor","year":"1982","unstructured":"Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Jt Surg Br. 1982;64(1):76\u201383. https:\/\/doi.org\/10.1302\/0301-620x.64b1.7068725.","journal-title":"J Bone Jt Surg Br."},{"issue":"6","key":"856_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/09638288.2017.1405083","volume":"41","author":"Y Nakahara","year":"2019","unstructured":"Nakahara Y, Kitoh H, Nakashima Y, et al. Longitudinal study of the activities of daily living and quality of life in japanese patients with fibrodysplasia ossificans progressiva. Disabil Rehabil. 2019;41(6):699\u2013704. https:\/\/doi.org\/10.1080\/09638288.2017.1405083.","journal-title":"Disabil Rehabil"},{"key":"856_CR7","unstructured":"Sohonos Product Monograph. 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00064435.PDF. Accessed 13 June 2022."},{"issue":"1","key":"856_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-017-0659-4","volume":"12","author":"M Di Rocco","year":"2017","unstructured":"Di Rocco M, Baujat G, Bertamino M, et al. International Physician Survey on Management of FOP: A Modified Delphi Study. Orphanet J Rare Dis. 2017;12(1):110. https:\/\/doi.org\/10.1186\/s13023-017-0659-4.","journal-title":"Orphanet J Rare Dis"},{"key":"856_CR9","doi-asserted-by":"crossref","unstructured":"Kaplan FS, Pignolo RJ, Al Mukaddam M, et al. Genetic disorders of heterotopic ossification. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley; 2018; p. 865\u201370.","DOI":"10.1002\/9781119266594.ch112"},{"key":"856_CR10","unstructured":"Kaplan F, Al Mukaddam M, Baujat G, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP, 1, 2019:24\u201345. https:\/\/d3n8a8pro7vhmx.cloudfront.net\/ifopa\/pages\/1042\/attachments\/original\/1628863428\/Authors_and_Consultants_%281%29.pdf?1628863428. Accessed 23 Aug 2023."},{"issue":"11","key":"856_CR11","first-page":"1243","volume":"10","author":"M Hind","year":"2009","unstructured":"Hind M, Stinchcombe S. Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. Curr Opin Investig Drugs. 2009;10(11):1243\u201350.","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"856_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1210\/endo.141.1.7283","volume":"141","author":"F De Luca","year":"2000","unstructured":"De Luca F, Uyeda JA, Mericq V, et al. Retinoic acid is a potent regulator of growth plate chondrogenesis. Endocrinology. 2000;141(1):346\u201353. https:\/\/doi.org\/10.1210\/endo.141.1.7283.","journal-title":"Endocrinology"},{"issue":"4","key":"856_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, Tung WE, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists. Nat Med. 2011;17(4):454\u201360. https:\/\/doi.org\/10.1038\/nm.2334.","journal-title":"Nat Med"},{"key":"856_CR14","unstructured":"ClinicalTrials.gov. Identifier: NCT03312634 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP (MOVE), 2017."},{"key":"856_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4655","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Hsiao EC, et al. Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial. J Bone Miner Res. 2022. https:\/\/doi.org\/10.1002\/jbmr.4655.","journal-title":"J Bone Miner Res"},{"key":"856_CR16","unstructured":"FDA. 2023. Sohonos highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215559s000lbl.pdf. Accessed 29 Aug 2023."},{"issue":"1","key":"856_CR17","first-page":"9","volume":"10","author":"B Brennan","year":"2007","unstructured":"Brennan B, Chiu Y, Berthelon L, et al. Effect of age and gender on the pharmacokinetics of R667, a novel agent for the treatment of emphysema, healthy volunteers. J Pharm Pharm Sci. 2007;10(1):9\u201316.","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"856_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/0091270005283836","volume":"46","author":"BJ Brennan","year":"2006","unstructured":"Brennan BJ, Brown AB, Kolis SJ, et al. Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. J Clin Pharmacol. 2006;46(2):222\u20138. https:\/\/doi.org\/10.1177\/0091270005283836.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"856_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1365-2125.2006.02808.x","volume":"63","author":"YY Chiu","year":"2007","unstructured":"Chiu YY, Roth MD, Kolis S, et al. Pharmacokinetics of a novel agent, R667, in patients with emphysema. Br J Clin Pharmacol. 2007;63(5):527\u201333. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02808.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"856_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.tripleo.2003.08.002","volume":"96","author":"AS Herford","year":"2003","unstructured":"Herford AS, Boyne PJ. Ankylosis of the jaw in a patient with fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96(6):680\u20134. https:\/\/doi.org\/10.1016\/j.tripleo.2003.08.002.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"856_CR21","doi-asserted-by":"crossref","unstructured":"World Declaration of Helsinki. Ethical principles for medical research involving human subjects. 2013;310(20):2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"856_CR22","unstructured":"ICH. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline. 2018. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 23 Aug 2023."},{"issue":"3","key":"856_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/js960085v","volume":"86","author":"WN Charman","year":"1997","unstructured":"Charman WN, Porter CJ, Mithani S, et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269\u201382. https:\/\/doi.org\/10.1021\/js960085v.","journal-title":"J Pharm Sci"},{"issue":"11","key":"856_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/j.1552-4604.1988.tb03129.x","volume":"28","author":"PJ McNamara","year":"1988","unstructured":"McNamara PJ, Jewell RC, Jensen BK, et al. Food increases the bioavailability of acitretin. J Clin Pharmacol. 1988;28(11):1051\u20135. https:\/\/doi.org\/10.1002\/j.1552-4604.1988.tb03129.x.","journal-title":"J Clin Pharmacol"},{"key":"856_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2230.2011.04033.x","volume":"36","author":"A Schmitt-Hoffmann","year":"2011","unstructured":"Schmitt-Hoffmann A, Roos B, Sauer J, et al. Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). Clin Exp Dermatol. 2011;36:18\u201323. https:\/\/doi.org\/10.1111\/j.1365-2230.2011.04033.x.","journal-title":"Clin Exp Dermatol"},{"key":"856_CR26","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 10295295, Palovarotene. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Palovarotene. Accessed 25 Aug 2023."},{"key":"856_CR27","unstructured":"FDA. Clinical Drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Accessed 23 Aug 2023."},{"key":"856_CR28","unstructured":"EMA. Fexofenadine hydrochloride 180mg film-coated tablets summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/3488\/smpc\/print. Accessed 25 Aug 2023."},{"key":"856_CR29","unstructured":"EMA. Assessment report: Sohons. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/sohonos-epar-refusal-public-assessment-report_en.pdf. Accessed 25 Aug 2023."},{"key":"856_CR30","doi-asserted-by":"publisher","DOI":"10.1530\/boneabs.7.OC27","author":"FS Kaplan","year":"2019","unstructured":"Kaplan FS, Hsiao EC, Baujat G, et al. Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP). Bone Abstracts. 2019. https:\/\/doi.org\/10.1530\/boneabs.7.OC27.","journal-title":"Bone Abstracts."},{"key":"856_CR31","first-page":"16","volume":"35","author":"RJ Pignolo","year":"2020","unstructured":"Pignolo RJ, Al Mukaddam M, Baujat G, et al. Palovarotene (PVO) for fibrodysplasia ossificans progressiva (FOP): data from the phase III MOVE trial. J Bone Miner Res. 2020;35:16\u20137.","journal-title":"J Bone Miner Res"},{"key":"856_CR32","volume-title":"Handbook of systemic drug treatment in dermatology","author":"PCM Van de Kerkhof","year":"2015","unstructured":"Van de Kerkhof PCM, Layton A. Handbook of systemic drug treatment in dermatology. 2nd ed. Taylor & Francis Group; 2015.","edition":"2"},{"key":"856_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-023-00815-x","author":"L Dube","year":"2023","unstructured":"Dube L, Haga N, Grogan D, et al. A pharmacokinetic, safety, and tolerability trial of palovarotene in healthy Japanese and non-Japanese participants. Eur J Drug Metab Pharmacokinet. 2023. https:\/\/doi.org\/10.1007\/s13318-023-00815-x.","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00856-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00856-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00856-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:02:35Z","timestamp":1699034555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00856-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00856-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"10 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was sponsored by Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RM: Employee of Ipsen; LD: Pharmacokinetic Consultant for Ipsen; JO:\u00a0Employee of Ipsen; K-HLQS: Coordinator of Ipsen FOP-program and MO-trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The original protocol (version 2.0, dated 14 December 2018; approved 20 December 2018), protocol amendment 1 (dated 7 January 2019; approved 17 January 2019), informed consent forms and updates for this trial were approved by the Institutional Review Board in accordance with pertinent country-specific regulatory requirements, and carried out in compliance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice Guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written and signed informed consent before engaging in any trial procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Qualified researchers may request access to patient-level study data that underlie the results reported in this publication. Additional relevant study documents, including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan and dataset specifications may also be made available. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of study participants. Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later. Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (). Any requests should be submitted to  for assessment by an independent scientific review board.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors thank Emma Lockyer, MChem, Jessica A. Buttress, PhD, and Oliver Palmer, BSc (Hons), of Costello Medical, UK, for providing medical writing and editorial support, which was sponsored by Ipsen in accordance with Good Publication Practice guidelines.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing Support"}},{"value":"Substantial contributions to study conception and design: RM, LD, JO, K-HLQS; substantial contributions to analysis and interpretation of the data: RM, LD, JO, K-HLQS; drafting the article or revising it critically for important intellectual content: RM, LD, JO, K-HLQS; final approval of the version of the article to be published: RM, LD, JO, K-HLQS.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}